TY  - JOUR
A1  - Birukov, Anna
A1  - Glintborg, Dorte
A1  - Schulze, Matthias B.
A1  - Jensen, Tina K.
A1  - Kuxhaus, Olga
A1  - Andersen, Louise B.
A1  - Kräker, Kristin
A1  - Polemiti, Elli
A1  - Jensen, Boye L.
A1  - Jørgensen, Jan S.
A1  - Dechend, Ralf
A1  - Andersen, Marianne S.
T1  - Elevated blood pressure in pregnant women with gestational diabetes according to the WHO criteria: importance of overweight
JF  - Journal of hypertension
N2  - Objective: Hypertension before and during early pregnancy has been associated with an increased risk of gestational diabetes mellitus (GDM) in retrospective analyses. We aimed to investigate the prospective blood pressure trackings in a population-based cohort of pregnant women, who were stratified according to their metabolic status in early third trimester. Methods: We recorded blood pressure longitudinally during pregnancy in 1230 women from the Odense Child Cohort, Denmark. Fasting glucose and insulin were measured at gestational weeks 28-30. Metabolic status was evaluated according to the WHO 2013 threshold for GDM (GDM-WHO: fasting plasma glucose >= 5.1 mmol/l), insulin and homeostatic model assessment of insulin resistance (HOMA-IR). Relationships between metabolic status in third trimester and blood pressure trajectories were evaluated with adjusted linear mixed models. Trajectory was defined as blood pressure records in pregnancy per 4 weeks interval. Results: Prevalence of GDM-WHO was 40% (498/1230). GDM-WHO was associated with 1.46 (0.22-2.70) mmHg higher SBP and 1.04 (0.07-2.01) mmHg higher DBP trajectories in the overall cohort. The associations were driven by differences in the overweight group, with 3.14 (1.05-5.25) mmHg higher SBP and 1.94 (0.42-3.47) mmHg higher DBP per 4 weeks in women with GDM-WHO compared with women without GDM-WHO. GDM-WHO was not associated with blood pressure in women with normal weight. Blood pressure trajectories were elevated across quartiles of insulin resistance. Conclusion: GDM-WHO is associated with higher blood pressure in pregnancy, and there appears to be a stronger effect in overweight women.
KW  - blood pressure
KW  - gestational diabetes mellitus
KW  - insulin resistance
KW  - overweight
KW  - pregnancy
KW  - WHO
Y1  - 2022
U6  - https://doi.org/10.1097/HJH.0000000000003196
SN  - 0263-6352
SN  - 1473-5598
VL  - 40
IS  - 8
SP  - 1614
EP  - 1623
PB  - Lippincott Williams & Wilkins
CY  - Philadelphia
ER  - 
TY  - JOUR
A1  - Algharably, Engi A. H.
A1  - Bolbrinker, Juliane
A1  - Lezius, Susanne
A1  - Reibis, Rona Katharina
A1  - Wegscheider, Karl
A1  - Völler, Heinz
A1  - Kreutz, Reinhold
T1  - Uromodulin associates with cardiorenal function in patients with hypertension and cardiovascular disease
JF  - Journal of hypertension
N2  - Objective:Common genetic variants in the gene encoding uromodulin (UMOD) have been associated with renal function, blood pressure (BP) and hypertension. We investigated the associations between an important single nucleotide polymorphism (SNP) in UMOD, that is rs12917707-G>T, and estimated glomerular filtration rate (eGFR), BP and cardiac organ damage as determined by echocardiography in patients with arterial hypertension.Methods:A cohort of 1218 treated high-risk patients (mean age 58.5 years, 83% men) with documented cardiovascular disease (81% with coronary heart disease) was analysed.Results:The mean values for 24-h SBP and DBP were 124.714.7 and 73.9 +/- 9.4mmHg; mean eGFR was 77.5 +/- 18.3ml/min per 1.73m(2), mean left ventricular ejection fraction was 59.3 +/- 9.9% and mean left ventricular mass index in men and women was 53.9 +/- 23.2 and 54.9 +/- 23.7g/m(2.7) with 50.4% of patients having left ventricular hypertrophy. A significant association between rs12917707 and eGFR was observed with T-allele carriers showing significantly higher eGFR values (+2.6ml/min per 1.73m(2), P=0.006) than noncarriers. This SNP associated also with left atrial diameter (P=0.007); homozygous carriers of the T-allele had smaller left atrial diameter (-1.5mm) than other genotype groups (P=0.040). No significant associations between rs12917707 and other cardiac or BP phenotypes were observed.Conclusions:These findings extend the previously documented role of UMOD for renal function also to treated high-risk patients with arterial hypertension and reveal a novel association with left atrial remodelling and thus a potential cardiorenal link modulated by UMOD.
KW  - blood pressure
KW  - cardiovascular complications
KW  - chronic kidney disease
KW  - genetics
KW  - hypertension
KW  - kidney function
KW  - organ damage
KW  - Tamm-Horsfall protein
Y1  - 2017
U6  - https://doi.org/10.1097/HJH.0000000000001432
SN  - 0263-6352
SN  - 1473-5598
VL  - 35
SP  - 2053
EP  - 2058
PB  - Lippincott Williams & Wilkins
CY  - Philadelphia
ER  - 
TY  - JOUR
A1  - Chaykovska, Lyubov
A1  - Alter, Markus L.
A1  - von Websky, Karoline
A1  - Hohmann, Margarete
A1  - Tsuprykov, Oleg
A1  - Reichetzeder, Christoph
A1  - Kutil, Barbara
A1  - Kraft, Robin
A1  - Klein, Thomas
A1  - Hocher, Berthold
T1  - Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension
JF  - Journal of hypertension
N2  - Objective:To investigate the effects of linagliptin alone and in combination with the angiotensin II receptor blocker (ARB), telmisartan on blood pressure (BP), kidney function, heart morphology and oxidative stress in rats with renovascular hypertension.Methods:Fifty-seven male Wistar rats underwent unilateral surgical stenosis of the renal artery [2-kidney-1-clip (2k1c) method]. Animals were randomly divided into four treatment groups (n=14-18 per group) receiving: telmisartan (10mg/kg per day in drinking water), linagliptin (89ppm in chow), combination (linagliptin 89ppm+telmisartan 10mg/kg per day) or placebo. An additional group of 12 rats underwent sham surgery. BP was measured one week after surgery. Hypertensive animals entered a 16-week dosing period. BP was measured 2, 4, 8, 12 and 16 weeks after the initiation of treatment. Blood and urine were tested for assessment of kidney function and oxidative stress 6, 10, 14 and 18 weeks after surgery. Blood and urine sampling and organ harvesting were finally performed.Results:Renal stenosis caused an increase in meanSD systolic BP as compared with the sham group (157.7 +/- 29.3 vs. 106.2 +/- 20.5mmHg, respectively; P<0.001). Telmisartan alone and in combination with linagliptin, normalized SBP (111.1 +/- 24.3mmHg and 100.4 +/- 13.9mmHg, respectively; P<0.001 vs. placebo). Telmisartan alone and in combination with linagliptin significantly prevented cardiac hypertrophy, measured by heart weight and myocyte diameter. Renal function measured by cystatin C was not affected by 2k1c surgery. Telmisartan significantly increased plasma concentration of cystatin C. 2k1c surgery initiated fibrosis in both kidneys. Telmisartan promoted further fibrotic changes in the clipped kidney, as measured by protein expression of Col1a1 and histology for interstitial fibrosis and glomerulosclerosis. In non-clipped kidneys, telmisartan demonstrated antifibrotic properties, reducing Col1a1 protein expression. Plasma levels of oxidized low-density lipoprotein were higher in the placebo-treated 2k1c rats as compared to sham-operated animals. The increase was abolished by linagliptin alone (P=0.03 vs. placebo) and in combination with telmisartan (P=0.02 vs. placebo). Combination therapy also significantly reduced plasma concentration of carbonyl proteins (P=0.04 vs. placebo).Conclusion:Inhibition of type 4 dipeptidyl peptidase with linagliptin did not counter BP-lowering effects of ARB in 2k1c rats. Linagliptin reduced lipid and protein oxidation in 2k1c rats, and this effect was BP-independent.
KW  - 2k1c renovascular hypertension
KW  - blood pressure
KW  - DPP4 inhibition
KW  - linagliptin
KW  - oxidative stress
Y1  - 2013
U6  - https://doi.org/10.1097/HJH.0b013e3283649b4d
SN  - 0263-6352
SN  - 1473-5598
VL  - 31
IS  - 11
SP  - 2290
EP  - 2299
PB  - Lippincott Williams & Wilkins
CY  - Philadelphia
ER  -